Bruker Corp Stock Price, News & Analysis

At the AACR Annual Meeting 2023, PreOmics launched a new BeatBox-based FFPE workflow aimed at enhancing tissue proteomics applications. This workflow allows high-throughput processing of up to 96 FFPE samples simultaneously, streamlining protocol by eliminating the need for xylene-based deparaffinization. The BeatBox system ensures fast processing, typically within 10 minutes, with a demonstrated increase in proteomic depth of 14% to 43% compared to traditional methods. Bruker Corporation will co-commercialize this innovative workflow alongside its timsTOF Pro mass spectrometer. With significant time savings and improved reproducibility, this development is poised to facilitate large-scale biobank projects and enhance research efficiency in pathology.

Canopy Biosciences and Enable Medicine have partnered to enhance the Canopy CellScape system for spatial biology through advanced analysis and cloud-based analytics. This collaboration integrates Enable's analysis tools, including cluster and neighborhood analysis, into the CellScape system, which allows for the detection of multiple protein targets and facilitates high-plex spatial proteomics.

The partnership aims to streamline data analysis for research applications, promising to enhance quantitative insights and discovery capabilities in spatial biology. This integrated data workflow will be showcased at the upcoming AACR annual meeting in April 2023.

Bruker Corporation announces the delivery of two 1.2 GHz Avance nuclear magnetic resonance (NMR) spectrometers to the University of Warwick and the University of Birmingham in the UK. These advanced instruments will enhance capabilities in research areas including energy storage, biofuels, and biomolecule structures. Expected installations in 2025 aim to empower UK scientists and students with state-of-the-art research tools. This initiative supports breakthroughs in renewable energy technologies and drug discovery, specifically targeting antibiotic resistance.

Bruker Corporation (NASDAQ: BRKR) has unveiled significant advancements in bioinformatics at the 19th US HUPO conference. Key highlights include the launch of the PaSER™ Novor sequencing algorithm, enhancing immunopeptidomics with real-time results derived from over 1.7 million data points. The updated dia-PASEF data analysis features library-free TIMS DIA-NN software, improving quantification accuracy. Additionally, a partnership with Mass Dynamics introduces advanced visualization tools for 4D-Proteomics. These innovations aim to enhance proteomic workflows, particularly for small tumor biopsy samples, and are expected to facilitate faster clinical outcomes.

Gauss Fusion GmbH, established in 2022, aims to develop a European GW-class fusion power plant by 2045. The venture secured €8 million in pre-seed financing in February 2023 and emphasizes close collaboration with European research institutions, including the Max Planck Institute. Gauss Fusion seeks to accelerate fusion energy development through a public-private partnership model, addressing the growing energy demand while supporting a net-zero society. The initiative has garnered political attention following breakthroughs in fusion energy, with expectations of industrial partnerships to enhance its goals.

Bruker Corporation (NASDAQ: BRKR) announced that Executive Vice President and CFO Gerald Herman will present at two upcoming investor conferences. The first is the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York City on March 2, 2023, at 9:30 a.m. ET. The second is the Cowen 43rd Annual Health Care Conference in Boston, MA, scheduled for March 6, 2023, at 2:10 p.m. ET. The presentations will be available via live webcasts on the Company’s Investor Relations website, with replays accessible for 90 days following the events.

Bruker Corporation (Nasdaq: BRKR) has declared a quarterly cash dividend of $0.05 per share, set to be paid on March 17, 2023. Stockholders on record as of March 1, 2023 will receive this dividend. The company focuses on providing high-performance scientific instruments and analytical solutions, aiding in breakthroughs in life-science research and diagnostics. This dividend reflects Bruker’s commitment to returning value to shareholders while continuing to invest in innovation and customer success.

Bruker Corporation reported Q4 2022 revenues of $708.4 million, up 3.6% year-over-year, with 8.9% organic growth. GAAP EPS was $0.66, while non-GAAP EPS rose 25.4% to $0.74. For FY 2022, revenues reached $2.531 billion, marking an increase of 4.7%, and 10.2% organic growth. GAAP EPS for FY 2022 was $1.99 with a non-GAAP EPS of $2.34, up 11.4%. Looking ahead, Bruker projects FY 2023 revenues of $2.81 to $2.86 billion with non-GAAP EPS guidance of $2.52 to $2.57, indicating 8% to 10% growth.